Leadsynbio Funding, Investors & Competitors

Leadsynbio has raised $118M across 4 funding rounds, most recently a $67M undisclosed-stage round in September 2026.

Last Leadsynbio funding round

$67M

Undisclosed stage · Sep 2026

Cumulative funding Leadsynbio raised

$118M

across 4 funding rounds

Key investors in Leadsynbio

  • Lilly Asia Ventures
  • Sherpa Healthcare Partners
  • Caixin Capital
  • Caixin Industry Fund
  • Hillhouse Investment
  • Oriza Holdings
  • GL Ventures
  • CICC Capital

Leadsynbio Overview

About Leadsynbio

Leadsynbio is a Suzhou Industrial Park-headquartered synthetic biology company recognized as a national Little Giant enterprise for specialized innovation. Established in 2015, it operates R&D centers in Suzhou and the United States alongside GMP-compliant manufacturing facilities in Hunan and Anhui provinces. The firm develops biosynthesis technologies via its proprietary platform, enabling large-scale production of core products for global customers. Leadsynbio integrates R&D, manufacturing, and supply chain capabilities to deliver high-efficiency biomanufacturing processes that cut costs and emissions for partners in multiple countries.


Founded

2015

HQ

ChinaSuzhou

Status

Privately held

Customer focus

B2B

Revenue model

Product sales

Leadsynbio Funding History

Leadsynbio has raised a total of $118M across 4 funding rounds.

Leadsynbio's first fundraising round was a $16M Series C in February 2022. The most recent completed round was a $67M undisclosed-stage round in September 2026.

Leadsynbio funding rounds

Leadsynbio funding rounds
DateStageInvestorsRaisedDeal Summary
Sep 2026Undisclosed stageCaixin Industry Fund; Jiangsu Industrial Investment Group; Suzhou Venture Capital; Caixin Capital; Maker Wisdom; Oriza Holdings$67MSuzhou Leadsynbio Technology Co., Ltd. completed a $67 million equity financing round in September 2026. Participants included Caixin Capital, Caixin Industry Fund, Jiangsu Industrial Investment Group, Maker Wisdom, Oriza Holdings, Suzhou Venture Capital, and Harvest Capital.
Jul 2025Series DJiashan Industrial; Caixin Capital; Hunan Xingxiang Investment; CICC Capital$14M-
Aug 2023Series DSherpa Healthcare Partners; Lilly Asia Ventures$21MLeadsynbio is a synthetic biology company based in Suzhou, China, with R&D centers in Suzhou Industrial Park and San Francisco, USA, and a production base in Changde, Hunan. It develops chemical and biological products for pharmaceuticals, health products, and agriculture using synthetic biology technology, supported by a platform and a team of over 100 people. The company has more than 20 products and focuses on commercialization, pipeline expansion, and green technology to support China's carbon goals. In early February (likely 2022 per source date), Leadsynbio completed a C-round financing exceeding RMB400 million, co-led by GL Ventures and Sherpa Healthcare Partners, with Asia Green Fund as a co-investor. Funds were allocated to accelerate commercialization of existing products, enhance the R&D pipeline, and expand the Hunan production base. A separate Series D round lists investors including Lilly Asia Ventures, Sherpa Healthcare Partners, New Hope Sichuan Venture Capital Fund, and U.S.-China Green Fund, with a last valuation of $313,650,000.
Feb 2022Series CGL Ventures (lead); Lilly Asia Ventures (lead); Sherpa Healthcare Partners (lead); Caixin Industry Fund; New Hope Sichuan Venture Capital Fund; Asia Green Fund; Hillhouse Investment; U.S.-China Green Fund; GF Qianhe Investment$16MLeadsynbio is a synthetic biology company founded in 2015 and based in Suzhou, China, focused on research, development, production, and sales of industrial biotechnology products for pharmaceuticals, nutritional health care, and animal health. It employs genetic modification, metabolic modification, enzyme modification, fermentation modification, chemical synthesis, and high-throughput screening, with R&D centers in Suzhou Industrial Park and San Francisco, and production bases in Hunan and Anhui. In early February 2022, corresponding to approximately 08/02/2022, Leadsynbio completed its Series C-II financing round of over RMB400 million, co-led by GL Ventures and Sherpa Healthcare Partners, with participation from Asia Green Fund and other investors including Caixin Industry Fund, GF Qianhe Investment, Hillhouse Investment, Hillhouse Ventures, Lilly Asia Ventures, New Hope Sichuan Venture Capital Fund, and U.S.-China Green Fund. The funds were allocated to accelerate commercialization of existing products, improve the R&D pipeline, and expand the Hunan production base. The company has a comprehensive synthetic biology technology platform and a research and development team of more than 100 people, with over 20 products in its pipeline targeting pharmaceuticals, health products, and agricultural products. Leadsynbio aims to support China's carbon neutrality goals through innovative green technology.

Who has invested in Leadsynbio?

17 investors have backed Leadsynbio across its funding rounds, including Lilly Asia Ventures, Sherpa Healthcare Partners, Caixin Capital, Caixin Industry Fund, Hillhouse Investment and Oriza Holdings.

Lead investors include GL Ventures, Lilly Asia Ventures and Sherpa Healthcare Partners.


Leadsynbio Investors

Investors in Leadsynbio by funding rounds participated
InvestorHQRoundsRoleFirst check
Caixin Industry FundChinaChangshan2ParticipantFeb 2022
Caixin CapitalChinaHunan2ParticipantJul 2025
Sherpa Healthcare PartnersChinaBeijing2LeadFeb 2022
Lilly Asia VenturesChinaShanghai2LeadFeb 2022
Jiashan IndustrialChinaChina1ParticipantJul 2025
Jiangsu Industrial Investment GroupChinaChina1ParticipantSep 2026
Suzhou Venture CapitalChinaSuzhou1ParticipantSep 2026
New Hope Sichuan Venture Capital FundChinaBeijing1ParticipantFeb 2022
Asia Green FundChinaChaoyang1ParticipantFeb 2022
GL VenturesChinaBeijing1LeadFeb 2022
Hillhouse InvestmentChinaBeijing1ParticipantFeb 2022
U.S.-China Green FundChinaBeijing1ParticipantFeb 2022
Maker WisdomAustraliaAustralia1ParticipantSep 2026

This data is available for Pro users. Sign up to see all 17 Leadsynbio investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Leadsynbio Competitors

Leadsynbio competitors include listed companies like Qinghai Salt Lake Industry, CF Industries, Industries Qatar and SABIC Agri-Nutrient, and private ones like Colossal Biosciences and Biobest.

Public and private companies comparable to Leadsynbio
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Qinghai Salt Lake IndustryChinaChinaPublicly listed$2.3B$1.2B$18B3.7x
CF IndustriesUnited StatesUnited StatesPublicly listed$7.1B$3.2B$17B2.7x
Industries QatarQatarQatarPublicly listed$4.4B$1.6B$17B5.2x
SABIC Agri-NutrientSaudi ArabiaSaudi ArabiaPublicly listed$3.5B$1.4B$15B3.8x
Colossal BiosciencesUnited StatesAustin, TXPrivate--$10B-
BiobestBelgiumWesterloPrivate--$1.5B-

Leadsynbio Public Comps

Leadsynbio is still privately-owned, but its public comps include Qinghai Salt Lake Industry, CF Industries, Industries Qatar, SABIC Agri-Nutrient, Zhejiang NHU, Fertiglobe, Cathay Biotech, PI Industries, K+S and Bloomage BioTechnology.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Qinghai Salt Lake Industry$2.3B$1.2B6.1x3.7x11.9x6.0x
CF Industries$7.1B$3.2B3.0x2.7x6.7x5.7x
Industries Qatar$4.4B$1.6B3.5x5.2x9.6x23.5x
SABIC Agri-Nutrient$3.5B$1.4B3.4x3.8x8.5x11.9x
Zhejiang NHU$3.3B$1.5B3.5x3.0x7.6x6.7x
Fertiglobe$2.8B$1B2.2x1.8x6.2x5.4x
Cathay Biotech$494M$116M7.3x6.3x31.3x24.5x
PI Industries$709M$203M3.4x3.3x12.0x14.3x

This data is available for Pro users. Sign up to see all Leadsynbio competitors and their valuation data.

Start Free Trial

Common questions about Leadsynbio

When was Leadsynbio founded?Leadsynbio was founded in 2015.
Where is Leadsynbio headquartered?Leadsynbio is headquartered in Suzhou, China.
Is Leadsynbio publicly listed?No, Leadsynbio is a private, VC-backed company.
How much funding has Leadsynbio raised?Leadsynbio has raised $118M across 4 funding rounds.
What was Leadsynbio's last funding round?Leadsynbio's last funding round was a $67M undisclosed-stage round in September 2026.
Who are Leadsynbio's investors?Leadsynbio's investors include Caixin Industry Fund, Caixin Capital, Sherpa Healthcare Partners, Lilly Asia Ventures, Jiashan Industrial, Jiangsu Industrial Investment Group, Suzhou Venture Capital, New Hope Sichuan Venture Capital Fund, Asia Green Fund, GL Ventures and 7 others.
Which companies are comparable to Leadsynbio?Companies comparable to Leadsynbio include Qinghai Salt Lake Industry, CF Industries, Industries Qatar, SABIC Agri-Nutrient, Colossal Biosciences and Biobest.

See companies similar to Leadsynbio

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial